文献速递肿瘤 PET/CT

机器人辅助腹腔镜前列腺癌根治术后前列腺特异性膜抗原靶向18F-DCFPyL PET/CT发现穿刺孔转移

Port-Site Metastasis Identified on Prostate-Specific Membrane Antigen-Targeted 18 F-DCFPyL PET/CT After Robot-Assisted Laparoscopic Radical Prostatectomy.
PubMed 文献 · Clin Nucl Med · 2023-01-12

本文报告一例74岁男性机器人辅助腹腔镜前列腺癌根治术后患者,尽管接受挽救性放疗仍出现生化复发,CT和骨扫描未见病灶,18F-DCFPyL PET/CT显示右侧腹直肌单发浓聚灶,超声引导穿刺活检免疫组化证实为前列腺转移性腺癌,提示穿刺孔转移。

要点

  • 前列腺癌微创术后穿刺孔转移是极罕见并发症。
  • CT和骨扫描阴性时,18F-DCFPyL PET/CT可发现穿刺孔转移灶。
  • 超声引导穿刺活检免疫组化可确诊穿刺孔转移。

核心结论

  • 前列腺癌微创术后穿刺孔转移是极罕见并发症,18F-DCFPyL PET/CT可识别CT和骨扫描未显示的穿刺孔转移,并经活检病理证实。

研究设计与样本

  • 本文为个案报告,报告一例74岁男性机器人辅助腹腔镜前列腺癌根治术后接受挽救性放疗、出现生化复发患者的诊治经过。

主要发现

  • 患者CT和骨扫描未见疾病证据时前列腺特异性抗原为4.6 ng/mL,18F-DCFPyL PET/CT显示右侧腹直肌单发浓聚灶,考虑为穿刺孔转移。
  • 超声引导穿刺活检免疫组化证实为前列腺转移性腺癌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Port-site metastasis is an extremely rare complication following minimally invasive oncologic surgery for prostate cancer. We present the case of a 74-year-old man who underwent robot-assisted laparoscopic radical prostatectomy followed by salvage radiotherapy. Despite treatment, he developed biochemical recurrence. However, there was no evidence of disease on CT and bone scan at a prostate-specific antigen of 4.6 ng/mL. Subsequently, 18 F-DCFPyL PET/CT revealed a solitary focus of intense uptake in the right rectus abdominis muscle that was felt to represent a port-site metastasis. Histopathologic evaluation with immunostaining following ultrasound-guided needle biopsy confirmed the presence of metastatic adenocarcinoma of the prostate.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zahed H, Laufer J, LeBlanc M, et al. Port-Site Metastasis Identified on Prostate-Specific Membrane Antigen-Targeted 18 F-DCFPyL PET/CT After Robot-Assisted Laparoscopic Radical Prostatectomy. Clin Nucl Med. 2023. PMID: 36630722. doi:10.1097/RLU.0000000000004544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。